Form 4: Director Acquires MAIA Biotechnology Shares

Director Stan Smith reported the acquisition of 75,000 shares of MAIA Biotechnology, Inc. common stock on June 1, 2026.

Summary

• Director Stan Smith acquired 75,000 shares of MAIA Biotechnology, Inc. common stock on June 1, 2026, at a weighted average price of $1.336 per share.
• The purchase was made in multiple transactions with prices ranging from $1.32 to $1.40 per share.
• Following this transaction, Mr. Smith beneficially owns a total of 1,519,178 shares of common stock.
• A portion of these shares are held indirectly through various trusts, including The Stan V. Smith Trust Dated 1993, and trusts for family members (Blake Sarai Teitei Smith IL Unif Trns Min Act, Gage Quentin Smith IL Unif Trns Min Act, and Travis Deo Zai Zai Smith IL Unif Trns Min Act).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to a director's significant stock purchase, indicating confidence in the company's value.

Positives

• Director's significant purchase of company stock indicates confidence in the company's future prospects.
• The acquisition of 75,000 shares by a director can be interpreted as a positive signal to the market.
• The total beneficial ownership of over 1.5 million shares by the director demonstrates a substantial personal investment in the company.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing, which is a statement of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, are often viewed as a positive indicator of management's belief in the company's intrinsic value and future growth potential within the biotechnology sector.

Stakeholder Impact

• Shareholders may view the director's purchase positively, potentially signaling confidence and a belief in future stock appreciation.
• Employees may see the director's investment as a sign of stability and commitment from leadership.

Key Dates

Recommendation

While an insider purchase is a positive signal, this Form 4 filing solely reports a transaction and does not provide operational or financial performance data. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor future financial reports for a more comprehensive view before making significant investment decisions.

Keywords

MAIA Biotechnology, Form 4, Insider Trading, Director Purchase, Common Stock, Beneficial Ownership, SEC Filing